- Home
- SDHY vs XFOR Comparison
SDHY vs XFOR Comparison
Compare SDHY & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDHY | XFOR |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.2M | 276.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SDHY | XFOR |
|---|---|---|
| Price | $16.65 | $3.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 76.9K | ★ 532.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,263.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.01 | $0.17 |
| 52 Week High | $17.18 | $6.63 |
Technical Indicators
Market Signals| Indicator | SDHY | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 46.37 |
| Support Level | $16.46 | $3.18 |
| Resistance Level | $16.62 | $3.45 |
| Average True Range (ATR) | 0.14 | 0.24 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 37.21 | 55.80 |
Price Performance
Historical ComparisonAbout SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.